https://scholars.lib.ntu.edu.tw/handle/123456789/495825
標題: | Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A 1chieve study | 作者: | Dieuzeide G. LEE-MING CHUANG Almaghamsi A. Zilov A. Chen J.-W. Lavalle-González F.J. |
公開日期: | 2014 | 出版社: | Elsevier Ltd | 卷: | 8 | 期: | 2 | 起(迄)頁: | 111-117 | 來源出版物: | Primary Care Diabetes | 摘要: | Aims Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens. Methods A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30. Results 1024 patients were included. At 24 weeks, glycated haemoglobin and fasting plasma glucose were significantly reduced from baseline in both cohorts (all p < 0.001). The proportion reporting any hypoglycaemia, major hypoglycaemia or nocturnal hypoglycaemia was significantly reduced after 24 weeks (all p < 0.05). No serious adverse drug reactions were reported. Both cohorts had significantly improved health-related quality of life (HRQoL; p < 0.001). Conclusions 24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced. This suggests that people with type 2 diabetes inadequately controlled on basal-bolus insulin regimens can consider biphasic insulin aspart 30. ? 2013 Primary Care Diabetes Europe. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901806502&doi=10.1016%2fj.pcd.2013.07.005&partnerID=40&md5=49815455f6be3bfbc5f580dbf775f4da https://scholars.lib.ntu.edu.tw/handle/123456789/495825 |
ISSN: | 1751-9918 | DOI: | 10.1016/j.pcd.2013.07.005 | SDG/關鍵字: | glucose; glycosylated hemoglobin; insulin; insulin aspart; insulin detemir; insulin glargine; isophane insulin; antidiabetic agent; biological marker; biphasic insulin; glargine; glucose blood level; glycosylated hemoglobin; hemoglobin A1c protein, human; insulin aspart; insulin aspart, insulin aspart protamine drug combination 30:70; isophane insulin; long acting insulin; adult; article; controlled study; drug efficacy; drug safety; female; glucose blood level; human; hypoglycemia; major clinical study; male; non insulin dependent diabetes mellitus; priority journal; quality of life; treatment outcome; Africa; aged; Asia; blood; chemically induced; clinical trial; Diabetes Mellitus, Type 2; drug administration; drug effects; drug substitution; injection; metabolism; middle aged; Middle East; multicenter study; Russian Federation; South and Central America; time; Adult; Africa, Northern; Aged; Asia; Biological Markers; Biphasic Insulins; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Substitution; Female; Hemoglobin A, Glycosylated; Humans; Hypoglycemia; Hypoglycemic Agents; Injections; Insulin Aspart; Insulin, Isophane; Insulin, Long-Acting; Latin America; Male; Middle Aged; Middle East; Quality of Life; Russia; Time Factors; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。